Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)
Launched by NANJING MEDICAL UNIVERSITY · May 4, 2025
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The patients are conformed to 2010 ACC/AHA guidelines for the diagnosis and treatment of thoracic aortic disease (TAD) within two weeks of onset;
- • Patients with acute aortic syndrome confirmed clinically and radiologically and planning to undergo emergency surgery were enrolled.
- • The patients' age between 18 \~90 years old.
- • Agree to participate in the study and sign the informed consent.
- Exclusion Criteria:
- • Patients allergic to Thymosin α1 or Ulinastatin;
- • Lactating women and pregnant women;
- • Patients with mental diseases, drug and alcohol dependence;
- • Refuse to participate in this study and refuse to sign the informed consent.
About Nanjing Medical University
Nanjing Medical University is a leading institution in medical education and research, dedicated to advancing health care through innovative clinical trials and scientific inquiry. With a strong emphasis on translating research findings into practical applications, the university fosters collaboration among multidisciplinary teams to address pressing health issues. Committed to ethical standards and patient safety, Nanjing Medical University is at the forefront of clinical research, contributing valuable insights and advancements in medical science to improve patient outcomes and enhance public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chengdu, Sichuan, China
Beijing, Beijing, China
Guangzhou, Guangdong, China
Shanghai, Shanghai, China
Patients applied
Trial Officials
Yong-feng Shao
Study Director
The First Affiliated Hospital with Nanjing Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported